You are here

IBD

AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral

AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral

Fierce Biotech

Flag link:

Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?

Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?

Motley Fool

Flag link:

Merck to buy inflammatory disease drugmaker Prometheus for $10.8B

Merck to buy inflammatory disease drugmaker Prometheus for $10.8B

BioPharma Dive

Prometheus Biosciences

Flag link:

FDA declines to approve Eli Lilly's bowel disease drug

FDA declines to approve Eli Lilly's bowel disease drug

Yahoo/Reuters

Flag link:

AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda

AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda

Fierce Pharma

ulcerative colitis

clinical trials

Flag link:

Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant

Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant

Biopharma Dive

Roivant Sciences

Flag link:

Sanofi and CytoReason target IBD in expanded collaboration

Sanofi and CytoReason target IBD in expanded collaboration

Pharma Live

Flag link:

Satisfai, Virgo, and Alimentiv to boost trials using AI-powered technology

Satisfai, Virgo, and Alimentiv to boost trials using AI-powered technology

Clinical Trials Arena

Satisfai Health

Virgo Surgical Video Solutions

clinical trials

artificial intelligence

Flag link:

Nestlé wagers $41M on Enterome's preclinical food allergy and IBD prospect

Nestlé wagers $41M on Enterome's preclinical food allergy and IBD prospect

Fierce Biotech

Flag link:

Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

BioSpace

Boehringer Ingelheim

Flag link:

Celsius Therapeutics heats up with $83M and an IBD drug on path to the clinic

Celsius Therapeutics heats up with $83M and an IBD drug on path to the clinic

MedCity News

Celsius Therapeutics

Flag link:

Using CRISPR to find a new drug target for multiple sclerosis, inflammatory bowel disease

Using CRISPR to find a new drug target for multiple sclerosis, inflammatory bowel disease

Fierce Biotech

multiple sclerosis

Flag link:

Another NASH player retreats from battered field after toxicology study flags potential delay

Another NASH player retreats from battered field after toxicology study flags potential delay

Endpoints

clinical trials

Flag link:

Building off Pfizer investment, microbiome-focused Vedanta expands new fundraise to launch 2 studies

Building off Pfizer investment, microbiome-focused Vedanta expands new fundraise to launch 2 studies

Endpoints

Flag link:

Ventyx bags $114M to test drugs against hot immunology targets

Ventyx bags $114M to test drugs against hot immunology targets

Fierce Biotech

Ventyx Biosciences

Flag link:

Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead

Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead

Endpoints

Flag link:

Lilly’s first crowdsourced digital health contest seeks solutions for IBD

Lilly’s first crowdsourced digital health contest seeks solutions for IBD

Fierce Pharma

innovation challenges

Flag link:

Microbiome Report for Week Ending 3/9/19

Microbiome Report for Week Ending 3/9/19

CP Wire

Infant Bacterial Therapeutics

atopic dermatitis

Flag link:

Microbiome Report for Week Ending 12/1/18

Microbiome Report for Week Ending 12/1/18

CP Wire

Evelo Biosciences

Kaleido Biosciences

Vedanta Biosciences

atopic dermatitis

Flag link:

Microbiome Report for Week Ending 12/1/18

Evelo Biosciences

Kaleido Biosciences

Vedanta Biosciences

atopic dermatitis

Flag link:

Pages